Drug Profile
Research programme: haemophilia therapeutics - Ipsen/Inspiration Biopharmaceuticals
Alternative Names: IB 1007; IB 1008Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Inspiration Biopharmaceuticals; Ipsen
- Developer Emergent BioSolutions
- Class Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haemophilia in USA (Parenteral)
- 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
- 10 Jun 2013 Cangene Corporation completes acquisition of IB 1007 and IB 1008 from Ipsen and Inspiration Biopharmaceuticals